Literature DB >> 30371560

What is the effect of alcohol consumption on the risk of chronic widespread pain? A Mendelian randomisation study using UK Biobank.

Marcus Beasley1,2, Maxim B Freidin3, Neil Basu1,2, Frances M K Williams3, Gary J Macfarlane1,2.   

Abstract

Studies have shown that moderate alcohol consumption is strongly associated with reduced reporting of chronic widespread pain (CWP). The study designs used, however, are prone to confounding and are not able to establish the direction of causality. The current study overcomes these problems using the Mendelian randomisation design to determine the effect of alcohol consumption on the likelihood of reporting CWP. The UK Biobank recruited 500,000 participants aged between 40 and 69 years. Data collected included questions on chronic pain and alcohol consumption, and biological samples providing genotypic information. Alcohol consumption was categorised as "weekly consumption" or "nonfrequent or infrequent." Participants were classified by genotype according to alleles of the rs1229984 single-nucleotide polymorphism, either "GG" or "AA/AG." Chronic widespread pain was defined as pain all over the body for more than 3 months that interfered with activities. Associations between genotype, CWP, and alcohol consumption were tested by logistic regression. Instrumental variable analysis was used to calculate the causal effect of weekly alcohol consumption on CWP. Persons with "GG" genotype had an increased risk of CWP (odds ratio [OR] 1.17, 99% confidence interval 1.01-1.35) and were more likely to consume alcohol weekly (OR 1.76, 1.70-1.81) compared to those with "AA/AG" genotype. Weekly consumption of alcohol was associated with reduced risk of CWP (OR 0.33, 0.31-0.35), but instrumental variable analysis did not show a causal effect of alcohol consumption on reducing CWP (OR 1.29, 0.96-1.74). An interpretation of observational population studies as showing a protective effect of alcohol on CWP is not supported.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30371560     DOI: 10.1097/j.pain.0000000000001426

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  5 in total

1.  Association Between Serum 25-Hydroxyvitamin D Concentrations and Chronic Pain: Effects of Drinking Habits.

Authors:  Keita Suzuki; Hiromasa Tsujiguchi; Sakae Miyagi; Thao Thi Thu Nguyen; Akinori Hara; Haruki Nakamura; Yukari Shimizu; Koichiro Hayashi; Yohei Yamada; Phat Minh Nguyen; Yuichi Tao; Takayuki Kannon; Atsushi Tajima; Hiroyuki Nakamura
Journal:  J Pain Res       Date:  2020-11-19       Impact factor: 3.133

2.  Classification of painful or painless diabetic peripheral neuropathy and identification of the most powerful predictors using machine learning models in large cross-sectional cohorts.

Authors:  Georgios Baskozos; Andreas C Themistocleous; Harry L Hebert; Mathilde M V Pascal; Jishi John; Brian C Callaghan; Helen Laycock; Yelena Granovsky; Geert Crombez; David Yarnitsky; Andrew S C Rice; Blair H Smith; David L H Bennett
Journal:  BMC Med Inform Decis Mak       Date:  2022-05-29       Impact factor: 3.298

3.  Comparison of chronic widespread pain prevalence with different criteria in two cohorts of rheumatoid arthritis.

Authors:  M Aronsson; S Bergman; E Lindqvist; M L E Andersson
Journal:  Clin Rheumatol       Date:  2021-11-23       Impact factor: 2.980

4.  Alcohol Consumption Is Associated with Poor Prognosis in Obese Patients with COVID-19: A Mendelian Randomization Study Using UK Biobank.

Authors:  Xiude Fan; Zhengwen Liu; Kyle L Poulsen; Xiaoqin Wu; Tatsunori Miyata; Srinivasan Dasarathy; Daniel M Rotroff; Laura E Nagy
Journal:  Nutrients       Date:  2021-05-10       Impact factor: 5.717

5.  Alcohol Consumption is Associated with Poor Prognosis in Obese Patients with COVID-19: a Mendelian Randomization Study using UK Biobank.

Authors:  Xiude Fan; Zhengwen Liu; Kyle L Poulsen; Xiaoqin Wu; Tatsunori Miyata; Srinivasan Dasarathy; Daniel M Rotroff; Laura E Nagy
Journal:  medRxiv       Date:  2020-11-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.